Copeptin in Differentiation of Polyuria and Polydipsia

This study has been completed.
Sponsor:
Collaborator:
Dr. Carson Liu Med Corp.
Information provided by:
University of Wuerzburg
ClinicalTrials.gov Identifier:
NCT01056887
First received: January 25, 2010
Last updated: April 22, 2011
Last verified: November 2010
  Purpose

The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy.

Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities.

The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably.

C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure.

Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.


Condition
Polyuria
Polydipsia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by University of Wuerzburg:

Estimated Enrollment: 50
Study Start Date: March 2008
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Primary Polydip, D. insipidus

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Healthy probands Patients with diabetes insipdus centralis totalis/ partials Patients with diabetes insipidus renalis Patients with primary polydipsia

Criteria

Inclusion Criteria:

  • Patients with polydipsia/ polyuria, with indication for performing a deprivation test
  • > 18 years

Exclusion Criteria:

  • dDAVP during the last 14d
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01056887

Locations
Germany
Univ Hospital Wuerzburg
Wuerzburg, Bavaria, Germany, 97080
Sponsors and Collaborators
University of Wuerzburg
Dr. Carson Liu Med Corp.
  More Information

No publications provided by University of Wuerzburg

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof. Dr. med. Bruno Allolio, FDAAA
ClinicalTrials.gov Identifier: NCT01056887     History of Changes
Other Study ID Numbers: 17121979, 33/07
Study First Received: January 25, 2010
Last Updated: April 22, 2011
Health Authority: Germany: The Bavarian State Ministry of the Environment and Public Health

Keywords provided by University of Wuerzburg:
diabetes insipidus
primary polydipsia
copeptin
Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test

Additional relevant MeSH terms:
Polyuria
Polydipsia
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Pathologic Processes

ClinicalTrials.gov processed this record on September 18, 2014